+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Co Ltd (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

  • Jul 17, 2024: nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease
  • Jul 16, 2024: PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
  • Jun 26, 2024: Takeda Announces New Assignments of Directors
  • May 21, 2024: Inspire and Takeda Researchers to Present Novel Study on Short Bowel Syndrome Patient Experience at DDW2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Takeda Pharmaceutical Co Ltd - Key Facts
  • Takeda Pharmaceutical Co Ltd - Key Employees
  • Takeda Pharmaceutical Co Ltd - Key Employee Biographies
  • Takeda Pharmaceutical Co Ltd - Major Products and Services
  • Takeda Pharmaceutical Co Ltd - History
  • Takeda Pharmaceutical Co Ltd - Company Statement
  • Takeda Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Takeda Pharmaceutical Co Ltd - Business Description
  • Product Category: Gastroenterology
  • Overview
  • Performance
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Other
  • Performance
  • Product Category: PDT Immunology
  • Overview
  • Performance
  • Product Category: Rare Genetics and Other
  • Performance
  • Product Category: Rare Hematology
  • Overview
  • Performance
  • Geographical Segment: Asia (excluding Japan)
  • Performance
  • Geographical Segment: Europe and Canada
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: Russia/CIS
  • Performance
  • Geographical Segment: U.S
  • Performance
  • R&D Overview
  • Takeda Pharmaceutical Co Ltd - Corporate Strategy
  • Takeda Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Takeda Pharmaceutical Co Ltd - Strengths
  • Takeda Pharmaceutical Co Ltd - Weaknesses
  • Takeda Pharmaceutical Co Ltd - Opportunities
  • Takeda Pharmaceutical Co Ltd - Threats
  • Takeda Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Takeda Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 17, 2024: nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease
  • Jul 16, 2024: PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
  • Jun 26, 2024: Takeda Announces New Assignments of Directors
  • May 21, 2024: Inspire and Takeda Researchers to Present Novel Study on Short Bowel Syndrome Patient Experience at DDW2024
  • May 14, 2024: Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
  • May 09, 2024: EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
  • May 09, 2024: Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
  • May 09, 2024: Takeda Announces With Sadness the Passing of Board Member Olivier Bohuon
  • May 09, 2024: Takeda Announces Enterprise-Wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
  • Apr 22, 2024: Takeda and others sign agreement to form early drug discovery incubation JV
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Takeda Pharmaceutical Co Ltd, Key Facts
  • Takeda Pharmaceutical Co Ltd, Key Employees
  • Takeda Pharmaceutical Co Ltd, Key Employee Biographies
  • Takeda Pharmaceutical Co Ltd, Major Products and Services
  • Takeda Pharmaceutical Co Ltd, History
  • Takeda Pharmaceutical Co Ltd, Other Locations
  • Takeda Pharmaceutical Co Ltd, Subsidiaries
  • Takeda Pharmaceutical Co Ltd, Joint Venture
  • Takeda Pharmaceutical Co Ltd, Key Competitors
  • Takeda Pharmaceutical Co Ltd, Ratios based on current share price
  • Takeda Pharmaceutical Co Ltd, Annual Ratios
  • Takeda Pharmaceutical Co Ltd, Interim Ratios
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Takeda Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Takeda Pharmaceutical Co Ltd, Performance Chart (2020 - 2024)
  • Takeda Pharmaceutical Co Ltd, Ratio Charts
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sumitomo Chemical Co Ltd
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Co
  • Kyorin Pharmaceutical Co Ltd
  • Celgene Corp
  • Biotest AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Grifols SA
  • Taisho Pharmaceutical Holdings Co Ltd
  • Bayer AG
  • AstraZeneca Plc
  • Amgen Inc
  • Novartis AG
  • AbbVie Inc